VITALE, PAOLA
 Distribuzione geografica
Continente #
NA - Nord America 116
AS - Asia 66
EU - Europa 41
SA - Sud America 28
AF - Africa 1
Totale 252
Nazione #
US - Stati Uniti d'America 110
SG - Singapore 30
BR - Brasile 22
HK - Hong Kong 12
IT - Italia 9
CN - Cina 8
DE - Germania 8
IE - Irlanda 6
RU - Federazione Russa 6
CA - Canada 5
FI - Finlandia 4
VN - Vietnam 4
BD - Bangladesh 3
IN - India 3
AR - Argentina 2
ES - Italia 2
GB - Regno Unito 2
JP - Giappone 2
PL - Polonia 2
PY - Paraguay 2
CO - Colombia 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EC - Ecuador 1
IQ - Iraq 1
MX - Messico 1
PH - Filippine 1
PK - Pakistan 1
TR - Turchia 1
UA - Ucraina 1
Totale 252
Città #
Dallas 35
Singapore 14
Ashburn 13
Hong Kong 12
Assago 8
Chandler 8
New York 8
Boardman 7
Dublin 6
Santa Clara 6
Jacksonville 5
Munich 5
Chicago 3
Los Angeles 3
Montreal 3
Batalha 2
Belo Horizonte 2
Frankfurt am Main 2
Hefei 2
Helsinki 2
New Delhi 2
Tokyo 2
Algiers 1
Asunción 1
Baghdad 1
Baie-D'Urfé 1
Balzar 1
Bauru 1
Beijing 1
Berlin 1
Boston 1
Brno 1
Bursa 1
Cabo Frio 1
Campinas 1
Can Tho 1
Caucaia 1
Chengdu 1
Chennai 1
Ciudad del Este 1
Da Nang 1
Denver 1
Dhaka 1
Faisalabad 1
Fortaleza 1
Guarujá 1
Guarulhos 1
Guiyang 1
Hanoi 1
Harvey 1
Ho Chi Minh City 1
Hortolândia 1
Krasnodar 1
L'aquila 1
Lappeenranta 1
Lawrence 1
London 1
Medellín 1
Monte Grande 1
Monte Santo de Minas 1
Moscow 1
Osasco 1
Peru 1
Princeton 1
Querétaro 1
Rio Branco 1
Rio das Flores 1
Rio de Janeiro 1
Seattle 1
Serrinha 1
São Luís 1
São Sebastião 1
The Dalles 1
Tomé-Açu 1
Toronto 1
Torres 1
Turku 1
Villa Krause 1
Warsaw 1
Wroclaw 1
Totale 208
Nome #
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 110
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 94
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 52
Totale 256
Categoria #
all - tutte 1.217
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.217


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 1 1 1 0 1 0
2021/20223 0 0 0 0 0 0 0 0 0 0 1 2
2022/202317 1 2 1 4 0 2 0 0 6 0 1 0
2023/202427 0 0 2 3 4 9 0 2 0 2 0 5
2024/202593 4 1 3 4 4 7 14 5 27 8 10 6
2025/2026107 7 21 32 21 21 5 0 0 0 0 0 0
Totale 256